pre-existing joint damage is based on the clinical data from a
multicenter trial in the U.S. that included 65 boys with severe hemophilia
A less than 30 months of age at study entry. Study participants were
followed for up to 5.5 years. This Joint Outcomes Study (JOS), conducted
over a 10-year period, was led by Marilyn J. Manco-Johnson, M.D., Professor
of Pediatrics and Associate Professor of Pathology in the Department of
Pediatrics, University of Colorado at Denver and Health Science Center, and
Director of the Mountain States Regional Hemophilia & Thrombosis Center at
the University of Colorado. Key findings from the JOS study, published in
the August 9, 2007 issue of The New England Journal of Medicine(2),
-- 93 percent of the participants in the routine prophylaxis group showed
normal joint function, in contrast to 55 percent in the episodic group.
-- Kogenate FS prophylaxis treatment was able to preserve the joint even if
the child had less than or equal to two bleeds per index joint.
-- Patients from the prophylaxis group were eight times more likely to have
damage-free joints than those from the episodic group.
-- The prophylaxis group had an 81.5 percent reduction in annual bleeding
frequency compared to the episodic group.
-- Overall, there was an 83 percent reduction in the risk for joint damage
in patients receiving prophylaxis from an early age.
-- Ten percent of the patients treated episodically experienced
life-threatening bleeds compared to zero patients treated
-- The most common adverse events were related to central venous access,
such as catheterization and catheter removal, central line infection and
The study was designed with special emphasis on the "index joints,"
including the elbow, knee and ankle joints, which are most prone to
bleeding in severe hemophPage: 1 2 3 4 5 Related medicine technology :1
. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy2
. FDA Approves First Hepatitis B Viral Load Test3
. U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinsons Disease4
. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 44355
. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer6
. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older7
. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)8
. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies9
. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria10
. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults11
. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection